<DOC>
	<DOC>NCT01733758</DOC>
	<brief_summary>This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in Japanese subjects with Type 2 diabetes mellitus.</brief_summary>
	<brief_title>A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects with diagnosis of Type 2 Diabetes Mellitus, treated with diet and exercise or a stable dose of 1 OAD at screening Body mass index (BMI) 17 to 40 kg/ m^2 inclusive Subjects who are OAD naïve, HbA1c between 7.0% and 10.0% at Screening and at Visit 2; for subjects who enter the study with 1 OAD, HbA1c between 6.5% and 9.5% at Screening and HbA1c between 7.0% and 10.0% at Visit 2 Creatinine clearance &gt;30 mL/min (calculated using the CockcroftGault formula) History of type 1 diabetes mellitus •Female subject is pregnant, lactating, or &lt;6 weeks postpartum• Clinically significant cardiovascular and/or cerebrovascular disease Current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator Serum amylase &gt;=3 ×ULN and/or serum lipase &gt;=2 × ULN and/or subject is experiencing any symptoms possibly related to pancreatitis Prior use of a TZD or GLP1R agonist within 4 months before Screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>albiglutide</keyword>
	<keyword>Japanese</keyword>
	<keyword>GSK716155</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>glucagon-like peptide 1</keyword>
</DOC>